NVO Earnings
Wednesday, May 06 2026
EPS Estimate
$6.96
$5.31 – $10.09
Revenue Estimate
$72.0B
Current Price
$40.46
Our Position
bearishNovo Nordisk partners with OpenAI for AI boost
est. revisions falling
(-27.2pp / 30d)
The AI partnership could speed drug development and operational efficiency, countering competitive threats and stabilizing Novo Nordisk's revenue decline and market share erosion.
Watch: Q1 2026 earnings and FDA decisions on Semaglutide compounding will clarify growth prospects and regulatory risks.
Data Signal Summary
2 bullish
1 bearish
Estimates up +6%
Put/call 0.4 (bullish skew)
Price downtrend
Key Context
Price Trend
downtrend
From 52w High
-1.1%
P/E Ratio
11.2
Est. Revisions (30d)
+5.9% 1up/0dn
Analyst Target (mean)
$47 $36–$66 +16%
Options P/C Ratio
0.38
Est. Dispersion
69% 3 analysts
Fund Convergence
moderate Citadel, Renaissance
Recent Activity
ae trade
5
2d ago
9d ago
11d ago
Explore more
